MOPA -- Media, All-In-One Agency, Blockchain Development
Social Media/Email
  • WORK
  • NEWS
  • SERVICE
  • CONTACT

New Institute For Global Health Discovery by Duke-NUS and Johnson & Johnson Opens in Singapore

6/21/2022

0 Comments

 
Picture
Picture
Jun.21.2022, Shanghai ------ Duke-NUS and Johnson & Johnson today announced the launch of the new J&J Satellite Center for Global Health Discovery (Satellite Center) at Singapore’s Duke-NUS Medical School, jointly established by Duke University and the National University of Singapore (NUS) as a graduate-entry medical school and research powerhouse. As the world’s largest and most broadly-based healthcare company, this first of the J&J Centers for Global Health Discovery (J&J Centers) in the Asia-Pacific region, the Satellite Center at Duke-NUS aims to help drive new solutions to address flaviviruses, which disproportionately impact communities across the region, by bringing together the talent and expertise of the world’s largest healthcare company with that of a leading academic institution.
Picture
An image from Duke-NUS
​The launch of the newest Satellite Center at Duke-NUS comes at a critical time. More than 400 million people are infected with flaviviruses each year and half of the global population is at risk, with Asia experiencing nearly three-quarters of the global burden. A warming planet means that billions more people could be impacted in the coming decades as the animal vectors that carry flaviviruses spread beyond the tropical regions where they have traditionally thrived.

Flaviviruses, like dengue and Zika, cause significant illness and death, yet no specific antiviral therapeutics are currently available. The frequency of dengue outbreaks has grown considerably over the past two decades, as evidenced by surges in places like Singapore. After experiencing its worst outbreak in history in 2020, Singapore is facing another major outbreak this year with more than 8,000 cases recorded in the first six months of 2022, exceeding the number of cases reported in the whole of 2021.
Picture
Ruxandra Draghia-Akli, M.D., Ph.D., Global Head, Global Public Health R&D at Janssen Research & Development, LLC
​“Singapore is one of the epicenters of the dengue threat as well as a leading innovation and research hub, making Duke-NUS a natural match for our vision to address flaviviruses by advancing innovative science,” said Ruxandra Draghia-Akli, M.D., Ph.D., Global Head, Global Public Health R&D at Janssen Research & Development, LLC. “Together, we can each leverage our unique strengths to translate action in the lab into solutions at the last mile that can help protect people against one of the world’s most significant and rising health threats.”

The J&J Centers for Global Health Discovery (J&J Centers) are a pillar of Johnson & Johnson’s efforts to advance early-stage, breakthrough science where research is needed most and health challenges are most acute. The latest Satellite Center builds on a longstanding collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Duke-NUS and marks the latest effort of the SingHealth Duke-NUS Academic Medical Centre to develop a collaborative Discovery District on its Campus to drive bench-to-bedside innovations. The collaboration will unite expertise from across the scientific community in the Asia-Pacific region to further cultivate Singapore as a hub of discovery research, while advancing R&D to address the unmet medical need of flaviviruses.
Picture
Professor Patrick Casey, Senior Vice-Dean for Research, Duke-NUS
​“The establishment of the Satellite Center at Duke-NUS builds upon our strong track record in flavivirus research and bench-to-bedside innovations, and will facilitate antiviral drug discovery for the prevention and treatment of flavivirus-associated diseases that are affecting communities in Southeast Asia and beyond. The collaboration is both timely, in view of the impending threat of climate change, and purposeful in realizing the School’s vision of transforming medicine and improving lives,” said Professor Patrick Casey, Senior Vice-Dean for Research at Duke-NUS.

Research at the Satellite Center at Duke-NUS will be led by Professor Subhash Vasudevan, Ph.D., Duke-NUS’ EID Program, and Olivia Goethals, Ph.D., Principal Scientist, Global Public Health R&D, Janssen Pharmaceutica NV.
Picture
Global Health Discovery QuickFire Challenge: Flavivirus Infections
Crowdsourcing Innovation through the Flavivirus QuickFire Challenge

Complementing the efforts of the Satellite Center, Johnson & Johnson Innovation, together with Johnson & Johnson Global Public Health, is proud to launch the Global Health Discovery QuickFire Challenge: Flavivirus Infections. The Challenge invites innovators to submit potentially ground-breaking ideas aiming to treat, control, or prevent flavivirus disease. The innovator(s) with the best potential solution will receive grant funding from a total pool of $300,000, virtual access to the JLABS Asia Pacific community, including a dedicated workstation for one year at JLABS @ Shanghai, and mentorship from experts at the Johnson & Johnson Family of Companies.

Applications will be accepted until November 4, 2022. To apply for the Global Health Discovery QuickFire Challenge: Flavivirus Infections, please visit the application portal: 
​https://jji.jnj/flavivirus

Johnson & Johnson’s Efforts to Tackle Dengue

The Company’s dengue compound discovery program started in 2007 to address the unmet medical need for treatment and prevention options for the dengue virus. The efforts at the new Satellite Center will build on more than a decade of work by Johnson & Johnson to accelerate innovation in the development of new potential preventive and therapeutic options for dengue.

In 2021, Johnson & Johnson announced the completion of a Phase 1, first-in-human clinical study evaluating a dengue-specific antiviral small molecule, with data from the study showing the antiviral to be safe and well-tolerated in humans. Additional preclinical data demonstrated the antiviral’s favorable safety profile and effectiveness at preventing dengue in mouse and non-human primate models.

“While there is an urgent need for new tools to address diseases like dengue, especially in the face of climate change, we believe we can accelerate research to move even faster,” said Marnix Van Loock, Ph.D., Lead for Emerging Pathogens, Global Public Health R&D, Janssen Pharmaceutica NV. “Building on our shared legacies, the Satellite Center at Duke-NUS will help jumpstart the innovation we need to strengthen the R&D pipeline and address the burden of these diseases.”

Duke-NUS has played a critical role in driving progress to tackle dengue, most recently by working with SingHealth’s Investigational Medicine Unit to conduct a Phase 2a clinical trial evaluating Janssen’s antiviral compound for the treatment of dengue.
Picture
An image from Johnson & Johnson
About the J&J Centers for Global Health Discovery

Johnson & Johnson is committed to addressing the dual gap in innovation and health equity through the establishment of the J&J Centers for Global Health Discovery. In joining forces with other institutions, leveraging regional networks and growing in scope, they provide long-term opportunities to mentor much-needed talent in the discovery sciences and empower people worldwide to drive R&D to address some of the most pressing challenges in global health.

The first J&J Satellite Center for Global Health Discovery launched in July 2021 at the London School of Hygiene & Tropical Medicine (LSHTM), which is focused specifically on developing cutting edge science, from biology to data sciences, to help build the next generation of drug regimens needed to treat all forms of tuberculosis (TB).

In April 2022, Johnson & Johnson launched the second Satellite Center for Global Health Discovery at the Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, in Cape Town, South Africa. Driven by some of the leading researchers in Africa and discovery science, the Satellite Center is focused on outpacing the rising threat of antimicrobial resistance (AMR) by accelerating innovation against multidrug-resistance Gram-negative bacteria (MDR-GNB), which are particularly concerning to public health.

While the past decade has seen a consistent decline in global funding for basic science, including discovery and pre-clinical development for neglected diseases, there are clear measures that can be taken to turn this tide. The J&J Centers are a crucial step in reversing this trend.

To learn more, visit jnj.com/global-public-health/discovery-centers.
Picture
About Duke-NUS
​

Establish by Duke University and the National University of Singapore, a a graduate medical school transforms medicine and improving lives in Singapore and beyond.

In April 2005, Duke University and the National University of Singapore signed a formal agreement under which the two institutions would partner to establish a new medical school for graduates in Singapore, to complement the National University of Singapore's existing undergraduate medical school. Under the agreement, the Singapore government would contribute significant investment over the first seven years to establish Duke-NUS as part of Singapore’s strategy to become a leading centre for medical research and education.

On 30 November 2010, following exceptionally strong progress in the first five-year phase, the Singapore government signalled their resounding support by extending the Duke and NUS strategic collaboration by another five years. Subsequently, On 2 June 2016, the stakeholders extended this collaboration through a third five-year agreement. 

Duke-NUS’ curriculum is patterned after that of the renowned Duke University School of Medicine in Durham, North Carolina. The School is part of the National University of Singapore system, but it is unique in that it is overseen by a Governing Board, including a Duke representative who has veto power over any academic decision made by the Board.
Picture
The Credo of Johnson & Johnson
About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.


Picture
About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism, & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.

Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal. Janssen Research & Development, LLC and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    News WorldWide

    MOPA
    ​Media, 
    All-In-One Agency, Blockchain Development

    Online Service

    ​Media
    ​Branding
    ​Celebrity Content
    ​Cultural Exchange
    Digital Marketing
    Public Relations
    Makeup
    Blockchain Project

    Our location:
    ​
    Auckland, ​New Zealand​
    Brisbane, Australia
    Shanghai, China
    Singapore


    Email:  info@mopa1.com
    Picture
     

    Archives

    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    April 2021
    March 2021
    February 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    August 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    October 2016
    November 2014
    August 2014
    July 2014
    April 2014
    March 2014
    February 2014
    October 2013
    September 2013
    June 2013

    Categories

    All
    Asia Pacific
    Australia
    Brazil
    Chile
    China
    Cuba
    Japan
    Latin America
    Mexico
    Singapore
    United States
    Venezuela
    Vietnam

    RSS Feed

Powered by Create your own unique website with customizable templates.